Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Clinical performance of senofilcon A investigational lens 
Protocol CR-6481Version: 3.0
                           
Date: 17 March 2022
Investigational Products: s enofilcon A prototype lens
Keywords:  Sphere platform, Test lens: senof ilcon A prototype, Contro l lens: delefilcon A
(Dailies Total 1), daily wear, daily disposable, dispensing, Revitalens, subjective performance. 
Statement of Compliance to protocol, GC P and applicable reg ulatory guidelines: 
This trial will be conducted in comp liance with the protocol, ISO [ZIP_CODE]:2020,
1 the 
International Council for Harmonization G ood Clinical Practice E6(R2) (ICH GCP),2the 
Declaration of Helsinki,3and all applicable regulatory requirements.
Confidentiality Statement:
This document contains confiden tial information, which should not be copi[INVESTIGATOR_530], referred to, 
released or published without written approval from [COMPANY_012] Vision Care, Inc. The information may not be disclosed to others except to the extent necessary to obtain Institutional 
Review Board/Independent Ethics Committee approval and informed consent, or as required 
by [CONTACT_19543], Federal and State Laws, as applicable. Persons to whom this information is 
disclosed must be informed that this information is privileged and confidential and that it 
should not be further disclosed without the written permission of [COMPANY_012] Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprietary to Johnson & Johns on Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document.
CR-6481, v 3.0  
 
Page 1 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
TABLE OF CONTENTS  
PROTOCOL TITLE, NUMBER, VERSION AND DATE ....................................................[ADDRESS_189330] Article Allocation .......................................................................................... 22  
5.2. Masking ................................................................................................................ 22  
5.3. Procedures for Maintaining and Breaking the Masking.......................................... 23  
6. STUDY INTERVENTION .......................................................................................... 23  
CR-6481, v 3.0  
 
Page 2 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.1. Identity of Test  Article s......................................................................................... 23  
6.2. Ancillary Supp lies/Produc ts .................................................................................. [ADDRESS_189331] Artic les.............................................................................. 25  
7. STUDY EVALUATIONS ........................................................................................... 26  
7.1. Time and Event Schedule...................................................................................... 26  
7.2. Detailed Study Pr ocedur es..................................................................................... 27  
VISIT 1 ....................................................................................................................... 27 
VISIT 2 ....................................................................................................................... 32 
FINAL EVALUATION............................................................................................... 34  
7.3. Unscheduled Visits................................................................................................ 35  
7.4. Laboratory Procedures .......................................................................................... 36  
8. SUBJECTS COMPLETION/WITHDRAWAL............................................................ 36  
8.1. Completion Criteria............................................................................................... 36  
8.2. Withdrawal/Discontinuation from the Study.......................................................... 37  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. [ADDRESS_189332] QUALITY COMPLAINTS .............. 41  
13. ADVERSE EVENTS ................................................................................................ 42  
13.1.  Definitions and Classifications........................................................................... 42  
13.2.  Assessing Adverse Events ................................................................................. 44  
13.2.1.  Causality As sessment ................................................................................. 45  
13.2.2.  Severity Assessment ................................................................................... 45  
13.3.  Documentation and Follow-Up of Adverse Events............................................. 46  
13.4.  Reporting Adverse Events ................................................................................. 47  
13.4.1.  Reporting Adverse Even ts to S ponsor ......................................................... 47  
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities
 [ADDRESS_189333] .................................................................................... 48  
CR-6481, v 3.0  
 
Page 3 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.6.  Reporting of Pregnancy ..................................................................................... [ADDRESS_189334] KEEPI[INVESTIGATOR_1645]/ARCHIVING ............................... 55  
15.1.  Electronic Case Report Form/Data Collection.................................................... [ADDRESS_189335] .................................................................................................. 55  
15.3.  Trial Registration on ClinicalTrials.gov ............................................................. 56  
16. DATA MANAGEMENT .......................................................................................... 56  
16.1.  Access to Source Data/Document ...................................................................... 56  
16.2.  Confidentiality of Informa tion........................................................................... 56  
16.3.  Data Quality Assurance ..................................................................................... 56  
16.4.  Data Monitoring Committee (D MC).................................................................. [ADDRESS_189336] (IEC/IRB)........... [ADDRESS_189337] RETENTION ............................................................................. 60  
20. FINANCIAL CONSIDERATIONS .......................................................................... 61  
21. PUBLICATION ....................................................................................................... 61  
22. REFERENCES......................................................................................................... 62  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) ...... 63  
APPENDIX B: PATIENT INSTRUCTION GUIDE............................................................ 82  
CR-6481, v 3.0  
 
Page 4 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ........................................ 83  
APPENDIX D: ...................................... [ADDRESS_189338] Reported Ocular Symptoms/Problems.................................................... 93  
 Front and Back Surface Lens Deposit Grading Procedure ................................... 95  
 Determination of Distance Spherocylindrical Refractive Error.......................... 100  
 Biomicrosc opy Scal e........................................................................................ 106 
 Distance and Near Snellen Visual Acuity Evaluation........................................ 112  
 Patient Reported Outcomes .............................................................................. 117  
 White Light Lens Surface Wettability ............................................................... 119  
APPENDIX E: IRIS COLOR SCALE............................................................................... 121  
APPENDIX F: STARTING LENS POWER GUIDANCE................................................. 122  
APPENDIX G: GUIDELINES FOR COVID-19 RISK MITIGATION.............................. 123  
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_1783] ........................ [ADDRESS_189339] OF TABLES
Table 1: Enrollment Strategy Ov erall .................................................................................. 20  
Table 2: Duration of Study Visits ........................................................................................ 21  
Table 3: Test Articles ......................................................................................................... . 23 
Table 4: Ancillary  Supplie s ................................................................................................. 24  
Table 5: Time and Events.................................................................................................... 26  
Table 6: Disallowed systemic medications........................................................................... 38  
Table 7: Disallowed systemic antihistamines....................................................................... 39  
Table 8: Examples of major and minor protocol deviations.................................................. 40  
Table 9: Descriptive Summary for the Primary and Secondary Endpoints at 2-week Follow-up 
from Historical and Interim Data......................................................................................... 49  
Table 10: Sample Size Estimation for th e Primary and Secondary Endpoi nts....................... [ADDRESS_189340] OF FIGURES
Figure 1: Study Flowchar t ................................................................................................... 13  
CR-6481, v 3.0  
 
Page 5 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
SYNOPSIS 
Protocol Title Clinical performance of senofilcon A investigational lens 
Sponsor JJVC, [ADDRESS_189341], Jacksonville, FL  [ZIP_CODE]
Clinical Phase Clinical trial phase: Claims
Design control phase: Phase [ADDRESS_189342] Article(s) Investigati onal Products: senofilcon A prototype as the Test 
lens
Approved Products: Dailies To tal 1 as the Control lens
Wear and Replacement 
SchedulesWear Schedule: daily wear
Replacement Schedule: daily disposable 
Objectives Primary Objectives: This study is being conducted to evaluate 
the clinical performance of an investigational soft contact [CONTACT_163065] a marketed product.
Study Endpoints Primary endpoint(s): Subjective responses concentrated on 
comfort towards the end of the day. 
Secondary endpoint(s): Subjectiv e responses concentrated on
digital device use, night driving, and all day comfort. Other observations: Subjective responses concentrated on 
other aspects of vision, comfort, and/or handling.
Study Design This study is a controlled, randomized, subject-masked, 2-arm 
parallel, 2-week dispensing, bilateral evaluation where the 
study lenses are worn for a minimum of 5 days per week and 
6 hours per day.
There will be a total of 2 visits:
1. Visit 1: Screening, baseline evaluation and lens 
fitting.
2. Visit 2: Follow-up evaluation, final evaluation. 
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main 
observations (Figure 1).
Sample Size Up to 360 subjects will be enrolled to complete approximately 
330 (approximately 165 in each arm).
CR-6481, v 3.0  
 
Page 9 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Study Duration Once enrolled, each subject will be in the study for [ADDRESS_189343] satisfy all of the following criteria to be enrolled in the study:
Inclusion Criteria after ScreeningThe subject must:
1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the form.
2. Appear able and willing to adhere to the instructions set 
forth in this clinical protocol.
3. Be between 18 and 39 (inclusive) years of age at the time 
of screening.
4. By [CONTACT_6270]-report, habitually wear spherical soft silicone 
hydrogel contact [CONTACT_35482] a daily wear or 
daily disposable wear modality (i.e. not extended wear
modality). Habitual wear is defined as a minimum of [ADDRESS_189344]‚Äôs vertex-corrected 
distance refraction must be between -1.00 and -6.00 DS 
(inclusive) in each eye.
8. The magnitude of the cylindrical component of the 
subject‚Äôs vertex-corrected distance refraction must be 
between 0.00 and 1.00 DC (inclusive) in each eye.
9. The best corrected, monocul ar, distance visual acuity 
must be 20/25or better in each eye.
CR-6481, v 3.0  
 
Page 10 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria ‚Äì 
Exclusion Potential subjects who meet any of the following criteria will be excluded from participating in the study:
Exclusion Criteria after ScreeningThe subject must not: 
1. Be currently pregnant or lactating.
2. Be currently using any ocular medications or have any 
ocular infection of any type.
3. By [CONTACT_6270]-report, have any oc ular or systemic disease, 
allergies, infection, or use of medication that the investigator believes might contraindicate or interfere 
with contact [CONTACT_13279], or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, 
tuberculosis), contagious immunosuppressive disease 
(e.g., Human Immunodeficiency Virus [HIV]), 
autoimmune disease (e.g. rheumatoid arthritis, Sj√∂gren‚Äôs syndrome), or history of serious mental illness or 
seizures. See section 9.[ADDRESS_189345] habitually worn rigid gas permeable (RGP) lenses, 
orthokeratology lenses, or hybrid lenses (e.g. 
SynergEyes, SoftPerm) within the past [ADDRESS_189346] 
clinical trial within 30 days prior to study enrollment.
8. Be an employee (e.g., Investigator, Coordinator, 
Technician) or immediate family member of an 
employee (including partner, child, parent, grandparent, 
grandchild or sibling of the employee or their spouse) of 
the clinical site.
Exclusion Criteria at Baseline Evaluation
The subject must not:
9. Have clinically significant (grade 3 or higher on the FDA 
grading scale) slit lamp findings (e.g., corneal edema, 
neovascularization or staini ng, tarsal abnormalities or 
bulbar injection) or other co rneal or ocular disease or 
abnormalities that the inve stigator believes might 
contraindicate contact [CONTACT_163066] (including entropi[INVESTIGATOR_2394], 
ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of 
recurrent corneal erosions, aphakia, moderate or above 
CR-6481, v 3.0  
 
Page 11 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
corneal distortion, herpetic keratitis). (Specify method of 
determination if needed).
10. Have a history of strabismus or amblyopia.11. Have fluctuations in vision due to clinically significant 
dry eye or other ocular conditions. 
12. Have had or have planned (within the study period) any 
ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
Disallowed Medications/Interventions  No ocular medications.
See section 9.1 for details regarding disallowed systemic 
medications.
Measurements and ProceduresSubjects will respond to a GSI/MRD questionnaire.
Microbiology or Other Laboratory TestingNone 
Study Termination The occurrence of an Unanticipated Adverse Device Effect 
(UADE) or Serious Adverse Event (SAE) for which a causal relationship to a test article ca nnot be ruled out, will result in 
stoppi[INVESTIGATOR_71144]. In the event of a UADE or SAE, the Sponsor Medical Monitor may 
unmask the treatment regimen of subject(s) and may discuss 
this with the Principal Investigator [INVESTIGATOR_35435].
Ancillary Supplies/ Study-Specific MaterialsRevitaLens, preservative-free artificial tears.
Principal Investigator(s) 
and Study 
Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.
CR-6481, v 3.0  
 
Page 12 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS
ADE   Adverse Device Effect
ADHD   Attention Deficit Hyperactivity Disorder
AE   Adverse Event/Adverse Experience
BSCVA  Best Spectacle Corrected Visual Acuity
CFR   Code of Federal Regulations
CLUE   Contact [CONTACT_163067]
   
D   Diopter 
DMC   Data Monitoring Committee
eCRF   Electronic Case Report Form
EDC   Electronic Data Capture
ETDRS   Early Treatment Diabetic Retinopathy Study FDA   Food and Drug Administration
GCP   Good Clinical Practice
HEV   High Energy Visible lightHIPAA   Health Insurance Portability and Accountability Act
HIV   Human Immunodeficiency VirusIB   Investigator‚Äôs Brochure
ICH   The International Council for Harmonization
IDE   Investigational Device Exemption
IEC   Independent Ethics Committee
IRB   Institutional Review Board
ISO   International Organization for Standardization
ITT   Intent-to-Treat
JJVC   [COMPANY_012] Vision Care, Inc.
LASIK   Laser-Assisted in Situ KeratomileusisLogMAR  Logarithm of Minimal Angle of Resolution
OD   Right Eye
OS   Left Eye
OU   Both Eyes
PIG   Patient Instruction Guide
PQC   Product Quality Complaint
PRK   Photorefractive KeratectomyPRO   Patient Reported Outcome
QA   Quality AssuranceSAE   Serious Adverse Event/Serious Adverse Experience
SAP   Statistical Analysis Plan
SAS   Statistical Analysis System
SD   Standard DeviationUADE   Unanticipated Adverse Device Effect
UV   Ultraviolet radiation
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect
VA   Visual Acuity
CR-6481, v 3.0  
 
Page 14 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1. INTRODUCTION AND BACKGROUND
This study will investigate the clinical perfor mance of an investigational Test lens against a
marketed Control lens. 
1.1. Name [CONTACT_163083] a senofilcon A-based p rototype against a commercially available 
marketed product Dailies Total 1 (DT1).  Further details about the test articles are found in 
section [ADDRESS_189347] version of the Investigator‚Äôs Brochure.
1.4. Summary of Known Risks and Benefits to Human Subjects
The risks of wearing soft contact [CONTACT_163068]‚Äôs 
Brochure and Informed Consent.  The material safety testing/lens release criteria was 
determined based on the Risk Assessment. Benefits to the subjects include the correction of 
their refractive error.
For the most comprehensive risk and bene fit information regarding senofilcon A-based 
investigational lens, refer to the latest version of the Investigator's Brochure.
1.5. Relevant Literature References and Prio r Clinical Data Relevant to Proposed 
Clinical Study
The package insert for the DT1 Control lens can be found in the appendices.  Prior clinical 
data of the investigational lens is summarized in the Investigator‚Äôs Brochure.
The literature is absent of any articles pertaining to the investigational lens.  Articles that 
pertain to the DT1 lenses do exist with a sampling shown here:
1. Wolffsohn, James, et al. "The influence of end of day silicone hydrogel daily disposable 
contact [CONTACT_163069], physiology and lens wettability." Contact [CONTACT_163070] 38.5 (2015): 339-344. 
2. Dumbleton, Kathryn A., et al. "A multi-country assessment of compliance with daily 
disposable contact [CONTACT_13279]." Contact [CONTACT_163071] 36.6 (2013): 304-312. 
3. Jayasree, Stephy VK, et al. "Quantification of water content in contact [CONTACT_163072]." 2021 46th International 
Conference on Infrared, Millim eter and Terahertz Wa ves (IRMMW-THz). IEEE.
CR-6481, v 3.0  
 
Page 15 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
4.0RQWpV·Ä®0LFy5REHUWHWDO2Q·Ä®H\HRSWLFDOTXDOLW\RIGDLO\GLVSRVDEOHFRQWDFWOHQVHVIRU
different wearing times." Ophthalmic and Physiological Optics 33.5 (2013): 581-591. 
2.STUDY OBJECTIVES , ENDPOINTS AND HYPOTHESES
2.1. Objectives 
Primary Objective(s)
This study is being conducted to ev aluate the clinical performance  of an investigational soft 
contact [CONTACT_163073] a marketed product.
2.2. Endpoints 
Primary Endpoint(s) : 
1. End of day comfort
xSubjects will respond to the question, ‚ÄúComfort at the End of the Day‚Äù  
. 
oResponse set: Very Satisfied, Satisfied, Neither Satisfied nor Dissatisfied, Dissatisfied, and Very Dissatisfied.
Secondary Endpoint(s): 
1. Digital device use
xSubjects will respond to the question, ‚ÄúReduction in the feeling of tired eyes from 
using a computer or other digital device‚Äù 
oResponse set: Not Applicable, Excellent, Very Good, Good, Fair, and Poor.
2. Comfort throughout the day  
xSubjects will respond to the question, ‚ÄúI  could wear these contact [CONTACT_163074] I wanted to‚Äù 
oResponse set: Strongly Disagree, Disagree , Neither Agree Nor Disagree, Agree, 
and Strongly Agree.
3. Comfortable vision while night driving  
xSubjects will respond to the question, ‚ÄúAbility to see comfortably while driving at 
night‚Äù 
oResponse set: Not Applicable, Excellent, Very Good, Good, Fair, and Poor.
Other Exploratory Endpoint(s):
Other exploratory endpoints including subjectiv e questions regarding comfort, vision, 
handling, and preferences, such as:
CR-6481, v 3.0  
 
Page 16 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
1. Clarity of distance vision
xSubjects will respond to the question, ‚ÄúClar ity of distance vision (i.e. looking at 
things that are more than [ADDRESS_189348] signs)‚Äù 
. 
oResponse set: Not Applicable, Excellent , Very Good, Good, Fair, and Poor.
2. Vision clarity throughout the day
xSubjects will respond to the question, ‚ÄúI was very satisfied by [CONTACT_163075]‚Äù
3. Didn‚Äôt have to think about the lenses
xSubjects will respond to the question, ‚ÄúI didn't have to think about my lenses until I was ready to take them out‚Äù 
oResponse set: Agree Strongly, Agree Somewhat, Neither Agree Nor 
Disagree, Disagree Somewhat, and Disagree Strongly.
4. Ability to see comfortably using digital devices
xSubjects will respond to the question, ‚ÄúAbility to see comfortably while using a
computer or other digital device‚Äù 
oResponse set: Not Applicable, Excellent, Very Good, Good, Fair, and Poor.
5. Tired eyes
xSubjects will respond to the question, ‚ÄúMy eyes felt tired‚Äù 
6. Eye fatigue
xSubjects will respond to the question, ‚ÄúEye fatigue‚Äù Response set: Always, Frequently, Occasionally, Rarely, Never, and Don't Know.
7. Vision at the end of the day
xSubjects will respond to the question, ‚ÄúI had very good vision at the end of the day‚Äù 
8. Vision in dim lighting
xSubjects will respond to the question, ‚ÄúI was satisfied with the quality of my vision 
in dim lighting‚Äù 
9. Dry eyes at the end of the day
xSubjects will respond to the question, ‚ÄúI have  experienced dry eyes at the end of 
the day‚Äù 
Response set for CLUE items: Strongly Disagree, Disagree, Neither Agree Nor Disagree, Agree, and Strongly Agree.  also ha s a ‚ÄúNot Applicable‚Äù response option. 
2.3. Hypotheses
The primary hypothesis must be met for the objective of this study to be satisfied:
CR-6481, v 3.0  
 
Page 17 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Primary Hypothesis 
1. After approximately two weeks of wear, the Test lens will have superior performance 
to the Control lens with respect to end of day comfort. 
The primary hypothesis must be met in order to begin testing any secondary hypotheses.
Secondary Hypotheses
1. After approximately two weeks of wear, the Test lens will have superior performance 
to the Control lens with respect to digital device use. 
2. After approximately two weeks of wear, the Test lens will have superior performance 
to the Control lens with respect to comfort throughout the day.  
3. After approximately two weeks of wear, the Test lens will have superior performance 
to the Control lens with respect to comfortable vision while night driving.
Exploratory Hypotheses
There will be no exploratory hypotheses. Al l exploratory endpoints will be descriptively 
summarized.
3. TARGETED STUDY POPULATION
3.1. General Characteristics 
Approximately [ADDRESS_189349] Group and approximately 180 will be 
targeted to the Control Group.  Within each lens gr oup, the intent is to complete 165 (330 total
subjects).  Enrolled subjects will be habitual wearers of silicone hydrogel spherical contact 
[CONTACT_13276].  All subjects will be the age of t18 and <40.  Subjects will wear the study contact [CONTACT_163076] a daily wear (DW) daily disposable (DD) basis for a total 
study duration of approximately 14 days (2 weeks) per subject.  
3.2. Inclusion Criteria
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
  Inclusion Criteria after Screening
The subject must:
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the form.
2. Appear able and willing to adhere to the inst ructions set forth in this clinical protocol.
3. Be between 18 and 39 (inclusive) years of age at the time of screening.
4. By [CONTACT_6270]-report, habitually wear spherical  soft silicone hydrogel contact [CONTACT_126101] a daily wear or daily disposable wear modality (i.e. not extended wear 
CR-6481, v 3.0  
 
Page 18 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
modality). Habitual wear is defined as a minimum of [ADDRESS_189350]‚Äôs vertex-corrected distance refraction must be 
between -1.00 and -6.00 DS (inclusive) in each eye.
8. The magnitude of the cylindrical component of the subject‚Äôs vert ex-corrected distance 
refraction must be between 0.00 and 1.00 DC (inclusive) in each eye.
9. The best corrected, monocular , distance visual acuity must be 20/25 or better in each 
eye.
3.3. Exclusion Criteria
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
Exclusion Criteria after Screening:
The subject must not:
1. Be currently pregnant or lactating.
2. Be currently using any ocular medications or have any ocular infection of any type.
3. By [CONTACT_6270]-report, have any ocul ar or systemic disease, allergies, infection, or use of 
medication that the investigator believes might contraindicate or interfere with 
contact [CONTACT_13279], or otherwise compromise study endpoints, including infectious 
disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., 
Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid 
arthritis, Sj√∂gren‚Äôs syndrome), or history of serious mental illness or seizures. See 
section 9.1for additional details rega rding excluded systemic medications. 
4. Have habitually worn rigid gas permeable  (RGP) lenses, orthokeratology lenses, or 
hybrid lenses (e.g. SynergEyes, SoftPerm) within the past [ADDRESS_189351] clinical trial within 14 days 
prior to study enrollment.
8. Be an employee (e.g., Investigator, Coor dinator, Technician) or immediate family 
member of an employee (including partner, child, parent, grandparent, grandchild or 
sibling of the employee or their spouse) of the clinical site.
CR-6481, v 3.0  
 
Page 19 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
5. TEST ARTICLE ALLOCATION AND MASKING
5.1. Test Article Allocation 
Use of the test articles will be randomized usi ng a lens fitting schedule supplied by [CONTACT_142452]. The clinical site will follow the lens fitting schedule provided and will complete 
enrollment according to the randomization list a nd will not pre-select or pre-assign subjects.
Randomly-permuted block randomization will be used to avoid bias in the assignment of 
subjects to treatment and to enhance the validity of statistical comparisons across treatment groups. A computer-generated randomization scheme will be used to randomly assign
subjects to one of the two lens groups (Test or Control). The randomization will be stratified 
by [CONTACT_163077] (daily disposable and daily wear reusable). The ratio of 
habitual wearers of daily disposable lenses to habitual wearers of daily wear reusable lenses 
is 7:3 within each study site (7 habitual wearers of daily disposable lenses versus 3 habitual 
wearers of daily wear reusable lenses). See T able 1. The random sche me will be generated 
using the PROC PLAN procedure from Statistical Analysis System (SAS) Software Version 
9.4 or higher (SAS Institute, Cary, NC).
[ADDRESS_189352] occurred prior to
randomization: 
‚Ä¢Informed consent must have been obtained.  
‚Ä¢The subject must have met all eligibility criteria. 
‚Ä¢The subject‚Äôs screening and baseline information must have been collected.
When dispensing test articles, the followi ng steps should be followed to maintain 
randomization codes:
1. Investigator or designee (documented on the Delegation Log) will consult the lens 
fitting schedule to obtain the test article assignment for that subject prior to dispensing. 
2. Investigator or designee will record the subject‚Äôs number on the appropriate line of the 
lens fitting schedule. 
3. Investigator or designee will pull the a ppropriate test articles from the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed 
outside the clinical site) or not, must be  recorded on the Test Article Accountability 
Log in the ‚ÄúDispensed‚Äù section. 
5.2. Masking
This is a single-masked trial. Subjects will be unaware of the identity of the investigational product.  The investigators may be aware of the study lenses based on a slight difference in 
lens color (the Test lenses will be slightly more turquoise in color than the Control lens). Investigators and clinical site  personnel involved in the data collection will not be masked as 
to the identity of the investigational product.
CR-6481, v 3.0  
 
Page 22 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.5. Storage Conditions
Test articles will be maintained at ambient temperatures at the clinical site. Test articles must 
be kept under secure conditions.
6.6. Collection and Storage of Samples
No samples will be collected as part of the study procedures.
When possible, any lens or test article asso ciated with an Adverse Event and/or a Product 
Quality Complaint must be retained and stored in a glass vial with moderate solution pending 
directions from the sponsor for potential return to JJVC.
6.7. Accountability of Test Articles
JJVC will provide the Investigator with suffici ent quantities of study articles and supplies to 
complete the investigation. The Investigator is asked to retain all lens shipment documentation for the test article accountability records. 
Test articles must be kept in a locked storage cabinet, accessible only to those assigned by [CONTACT_35500]. The Investigator may delegate this activity to authorized study site 
personnel listed on the Site  Delegation Log. All test articles must be accounted. This includes:
1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued 
for the subject to replace appropriately between visits.  
2. What was returned to the Investigator unused, including expi[INVESTIGATOR_93785]. 
3. The number and reason for unplanned replacements. 
The Investigator will collect all unused test artic les from the subjects at the end of the subject‚Äôs 
participation. Subject returned unused test ar ticles must be separated from the clinical study 
inventory of un-dispensed test articles and must  be labeled with the subject number and date 
of return. Following final reconciliation of test articles by [CONTACT_2037], the Investigator or monitor will return all unused test articles to JJVC .
If there is a discrepancy between the shipment  documents and the contents, contact [CONTACT_163078] . 
Reference Site Instructions for Test Article Receipt and Test Article Accountability for additional information.
CR-6481, v 3.0  
 
Page 25 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
8.2. Withdrawal/Discontinuation from the Study
A subject will be withdrawn from the study for any of the following reasons:
xSubject withdrawal of consent. 
xSubject not compliant to protocol such as st udy lens wear time or habitual lens wear 
while enrolled in the study.
xSubject lost to follow-up. 
xSubject no longer meets eligibility criteria (e.g. the subject becomes pregnant). 
xSubject develops significant or serious adverse events necessitating discontinuation of 
study lens wear. 
xSubjects who have experienced a Corneal Infiltrative Event (CIE). 
xInvestigator‚Äôs clinical judgment regarding the subject safety reasons (that it is in the best interest of the subject to stop treatment). 
xSubject missed a study visit . 
xSubject not compliant with study lens wear  schedule (i.e. wears study lenses less than 
at least [ADDRESS_189353] 5 days a week over the 2 week wear period)
xSubject not successfully dispensed due to lack of efficacy and safety including poor vision, poor comfort or unacceptable fit. 
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled). 
xComplete the Final Evaluation, indicating th e reason that the subject was discontinued 
from the study. 
xRecord the spherocylindrical refraction with best corrected distance visual acuity. 
xCollect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in section 7.2. 
xCollect all unused test article(s) from the subject. 
xMake arrangements for subject care, if needed, due to their study participation
Additional subjects will be enrolled if a subj ect discontinues from the study prematurely. 
In cases where a subject is lost to follow-up, every possible effort must be made to contact [CONTACT_35508]/withdrawal. The measures taken to follow 
up must be documented including two written attempts and a certified letter (or equivalent) as the final attempt. 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION
Concomitant medications will be  documented during screening and updated during the study.  
xDisallowed medications for this study include : medications that may interfere with 
contact [CONTACT_13279] (see section 9.1).  Habitual medications used by [CONTACT_163079].
xConcomitant therapi[INVESTIGATOR_35443]: NA
CR-6481, v 3.0  
 
Page 37 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The 
study can be terminated by [CONTACT_35511], if in their opi[INVESTIGATOR_1649], after a discussion with JJVC, it is determined that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB, if applicable) will evaluate all adverse events. If it is determined that 
an adverse event presents an unreasonable risk, the investigation, or that part of the 
investigation presenting the risk, will be terminated as soon as possible.
Should the study be terminated (either prematur ely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by [CONTACT_35512].
12. PROCEDURE FOR HANDLING PR ODUCT QUALITY COMPLAINTS
A Product Quality Complaint (PQC) refers to an y written, electronic, or oral communication 
that alleges deficiencies related to the identity, quality, durability, reliability, safety, 
effectiveness or performance of test articles after they have been released for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following ar e not considered product quality complaints:
xSubject satisfaction inquiries reported via ‚ÄúSubjective Questionnaires‚Äù and ‚ÄúPatient 
Reported Outcomes (PRO).‚Äù 
xClinical test articles that are stored improperly or damaged after receipt at the 
investigational site. 
xLens replacements that occur due to drops/fall-outs. 
xDamage deemed by [CONTACT_35513], 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by [CONTACT_423]. 
Within [ADDRESS_189354] be 
recorded in the EDC system, which will trigger an automatic email notification to the 
appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use 
is not configured to send automatic notifications or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_19568]: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor Awareness). 
xWho received the complaint. 
CR-6481, v 3.0  
 
Page 41 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xStudy number. 
xClinical site information (contact  [CONTACT_2300], site ID, telephone number). 
xLot number(s). 
xUnique Subject Identifier(s). 
xIndication of who first observed comp laint (site personnel or subject). 
xOD/OS indication, along with whether the lens was inserted. 
xAny related AE number if applicable. 
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.). 
xEye Care Provider objective (slit lamp) findings if applicable. 
xConfirmation of product availability for return (and tracking information, if available), 
or rationale if product is not available for return (Refer to Form Control No.
for test article return instructions). 
Once a complaint is received, it will be asse ssed by [CONTACT_19569], CRA, or trained site personnel 
to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or traine d site personnel will follow section 13 of this 
protocol. If the AE/SAE was potentially the resu lt of a product quality related deficiency, these 
procedures also applies and will be executed in parallel.  
In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the 
PQC forms will be marked ‚ÄúIntentionally Left Bla nk‚Äù or ‚ÄúILB‚Äù.  Justification for ILB must be 
documented. 
13. ADVERSE EVENTS
13.1. Definitions and Classifications
Adverse Event (AE) ‚Äì An AE is ‚Äúany untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investigational medical device.‚Äù  
Note : This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. For users or other persons, this definition is 
restricted to events related to investigational medical devices.1
An AE includes any condition (including a pre-existing condition) that:
1. Was not present prior to the study, but appeared or reappeared following initiation of 
the study. 
2. Was present prior to the study but worsened during the study. This would include any 
condition resulting from concomitant illnesses, reactions to concomitant medications, 
or progression of disease states. 
CR-6481, v 3.0  
 
Page 42 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon learning of the event.
Serious Adverse Event (SAE) ‚Äì An SAE is any adverse event that led to any of the following: 
xDeath
xSerious deterioration in the health of the subject that resulted in any of the following:
xLife-threatening illness or injury
xPermanent or persistent impairment of a body structure or a body function
xHospi[INVESTIGATOR_35448]-threatening illness or injury or 
permanent impairment to a body structure or a body function.
xChronic disease
xFoetal distress, foetal death or a congen ital physical or mental impairment of birth 
defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis 
xHypopyon 
xHyphemia 
xPenetration of Bowman‚Äôs Membrane
xPersistent Epi[INVESTIGATOR_35449]  ‚Äì are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact [CONTACT_129813], but 
not limited to the following:
xContact [CONTACT_35516] (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epi[INVESTIGATOR_32955] (SEALs)
xAny Temporary Loss of > 2 Lines of BSCVA
xOther grade 3 or higher corneal findings, such as abrasions or edema
CR-6481, v 3.0  
 
Page 43 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xNon-contact [CONTACT_71176] - e.g. Epi[INVESTIGATOR_71155] (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates te mporary lens discontinuation > 2 weeks
Non-Significant Adverse Events  ‚Äì are defined as those events that are usually asymptomatic 
and usually do not warrant discontinuation of c ontact lens wear but may cause a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure.
Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact [CONTACT_19573][INVESTIGATOR_19534] (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact [CONTACT_35518], which 
necessitates temporary lens discontinuation < [ADDRESS_189355] (ADE) ‚Äì An ADE is an ‚Äúadverse event related to the use of an 
investigational medical device.‚Äù 
Note 1 : This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation,  installation, or operation, or any malfunction 
of the investigational medical device.
Note 2 : This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device.[ADDRESS_189356] (UADE) ‚Äì A UADE is any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the test 
article, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational plan , Investigator‚Äôs Brochure or protocol, or any 
other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects.
13.2. Assessing Adverse Events
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization will include:
CR-6481, v 3.0  
 
Page 44 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xSeriousness/Classifications (see definition in section 13.1). 
xCausality or Relatedness ‚Äì i.e. the relations hip between the test article, study treatment 
or study procedures and the adverse event (not related, unlikely related, possibly 
related, or related - see definition in section 13.2.1). 
xAdverse Event Severity ‚Äì Adverse event severity is used to assess the degree of 
intensity of the adverse event (mild, moderate, or severe - see definition in 
section 13.2.2). 
xOutcome ‚Äì not recovered or not resolved, recovering or resolving, recovered or 
resolved with sequelae, recovered or resolved, death related to adverse event, or
unknown. 
xActions Taken ‚Äì none, temporarily discontinued, permanently discontinued, or other. 
13.2.1. Causality Assessment
Causality Assessment ‚Äì A determination of the relationshi p between an adverse event and the 
test article. The test article relationship for each adverse event should be determined by [CONTACT_19575]:
xNot Related- An adverse event that is not re lated to the use of the test article, study 
treatment or study procedures. 
xUnlikely Related ‚Äì An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not likely. 
xPossibly Related ‚Äì An adverse event that might be due to the use of the test article, or to the study treatment or study procedures. An alternative explanation, e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is 
reasonable. Therefore, the causal relationship cannot be excluded. 
xRelated ‚Äì An adverse event that is listed as a possible adverse effect (device) or adverse 
reaction (drug) and cannot be reasonably expl ained by [CONTACT_4867], e.g. 
concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirme d by [INVESTIGATOR_5328]-challenge and re-challenge. 
13.2.2. Severity Assessment
Severity Assessment ‚Äì A qualitative assessment of the degree of intensity of an adverse event 
as determined by [CONTACT_129814]/her by [CONTACT_3433] e subject. The assessment of 
severity is made irrespective of test article, study treatment or study procedure relationship or 
seriousness of the event and should be evaluated according to the following scale:
xMild ‚Äì Event is noticeable to the subject but is easily tolerated and does not interfere 
with the subject‚Äôs daily activities. 
xModerate ‚Äì Event is bothersome, possibl e requiring additional therapy, and may 
interfere with the subject‚Äôs daily activities. 
xSevere ‚Äì Event is intolerable, necessitates additional therapy or alteration of therapy 
and interferes with the subject‚Äôs daily activities. 
CR-6481, v 3.0  
 
Page 45 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.3. Documentation and Follow-Up of Adverse Events
The recording and documenting of adverse even ts (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure. Adverse events 
reported before the use of test article, start of  study treatment, or study procedures will be 
recorded as medical history. However, if the condition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the subject‚Äôs 
exit from the study will be recorded as adverse events at the discretion of the Investigator.
Upon finding an adverse event, the Principal I nvestigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.  Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic reactions not meeting the criteria for ‚Äúserious 
adverse events‚Äù shall be captured on the appropriate case report form or electronic data system. 
All adverse events occurring while the subject is enrolled in the study must be documented 
appropriately regardle ss of relationship.  
It is the Investigator‚Äôs responsibility to maintain  documentation of each reported adverse event. 
All adverse events will be followed in accordance with applicable licensing requirements. Such 
documentation will include the following:
xAdverse event (diagnosis not symptom). 
xDrawings or photographs (where appropria te) that detail the finding (e.g., size,
location, and depth, etc.). 
xDate the clinical site was notified. 
xDate and time of onset. 
xDate and time of resolution. 
xAdverse event classification, severity, and relationship to test articles, as applicable. 
xTreatment regimen instituted (where appropriate), including concomitant medications prescribed, in accordance with applicable licensing requirements. 
xAny referral to another health care provider if needed. 
xOutcome, ocular damage (if any). 
xLikely etiology. 
xBest corrected visual acuity at the discovery of the event and upon conclusion of the event, if the AE is related to the visual system. 
Upon discovery of an AE that is deemed ‚Äòpossibly related‚Äô or ‚Äòrelated‚Äô to the test article or 
study procedures (whether related to the visual system or not), an AE review form 
must be completed. Additiona l dated and initialed entries s hould be made at follow-up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he/s he will complete the Corneal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the 
CR-6481, v 3.0  
 
Page 46 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be recorded. 
Changes in the severity of an AE shall be doc umented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.
Subjects who present with an adverse event shall be followed by [CONTACT_737], within 
licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or 
been satisfactorily resolved. If further treatment  beyond licensure is required, the patient will 
be referred to the appropriate health care provi der. The Investigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in the study. If 
a subject is discontinued from the study, it will be the responsibility of the Investigator to 
record the reason for discontinuation. The Invest igator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse 
events related to the test artic le, study treatment or study procedures, as of the final study visit 
date, should be followed to resolution of the adve rse event or until referral to an appropriate 
health care provider, as recommended by [CONTACT_737]. Non-ocular adverse events that are 
not related to the test article, study treatment , or study procedures may be recorded as 
‚Äúongoing‚Äù without further follow-up. 
13.4. Reporting Adverse Events 
The Investigator will notify the Sponsor of an  adverse event by e-mail,  facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for any non-significant adverse event. In addition, 
a written report will be submitted by [CONTACT_163080]/IRB according to 
their requirements (section 13.4.2). The report will comment whether the adverse event was 
considered to be related to the test article, study treatment or study procedures.
13.4.1. Reporting Adverse Events to Sponsor
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e-mail or telephone, but no later than 24 hours 
following discovery of the event. The Inves tigator is obligated to pursue and obtain 
information requested by [CONTACT_35519]. All subjects experiencing a serious/significant advers e event must be followed up and all outcomes 
must be reported.
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.
In the event of a serious/significant adverse event, the Investigator must:
CR-6481, v 3.0  
 
Page 47 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xNotify the Sponsor immediately. 
xObtain and maintain in the subject‚Äôs records all pertinent medical information and 
medical judgment for colleagues who assisted in the treatment and follow-up of the 
subject. 
xProvide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article. 
xNotify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure according to 
national regulations. 
Unanticipated (Serious) Adverse Device Effect (UADE)In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than [ADDRESS_189357] report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within [ADDRESS_189358].
Non-Serious Adverse Events
All non-serious adverse events, including non-seri ous adverse device effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from discovery.
13.4.2. Reporting Adverse Events to the Re sponsible IEC/IRB and Health Authorities
Adverse events that meet the IEC/IRB requireme nts for reporting must be reported within the 
IEC/IRB‚Äôs written guidelines. Each clinical site will refer to and follow any guidelines set forth 
by [CONTACT_19581]/IRB. Each clinical site will refer to and follow any guidelines set forth 
by [CONTACT_19582].
The Sponsor will report applicable Adverse Events  to the local health authorities according to
the written guidelines, including reporting timelines. 
13.5. Event of Special Interest
None.
13.6. Reporting of Pregnancy
Subjects reporting pregnancy (by [CONTACT_6270]-report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact [CONTACT_129815], but due to 
general concerns relating to pregnancy and contact [CONTACT_19584]. Sp ecifically, pregnant women are 
discontinued due to fluctuations in  refractive error and/or visual acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.
CR-6481, v 3.0  
 
Page 48 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
hypothesis is rejected. According to the trun cated Hochberg procedure with a truncation 
fraction of ›Ç=‡¨µ
‡¨∂, the larger p-value obtained from these t wo secondary tests will be compared 
to the endpoint-specific alpha level 0.0375, and t he smaller p-value will be compared to the 
endpoint-specific alpha level 0.025.  
xIf the secondary test with the larger p-value is successful and the one with the smaller 
p-value is not successful, then alpha of 0. [ADDRESS_189359] secondary endpoint 
(comfortable vision while night driving).  
xIf the secondary test with the smaller p-value is successful and the one with the larger 
p-value is not successful, then alpha of 0.[ADDRESS_189360] secondary endpoint cannot 
be tested. 
14.5. Primary Analyses
The primary analysis will be conducted on th e Intent-to-Treat (ITT) population with observed 
cases (use only available datapoints and no imputation for missing data). 
End of Day Comfort
End of Day Comfort will be measured using th e individual item ‚ÄúComfort at the End of the 
Day‚Äù at 2-week follow-up. Item responses will be converted into a binary variable for the 
purpose of analysis (Very Satisfied or Satisfied = 1 and others = 0). The dichotomized item 
responses will be analyzed using a generalized linear mixed model with a binomial distribution 
and the logit as the link function. The model will include lens type as a fixed effect and site as a (G-side) random effect. Other subject characteristics such as ag e, gender, race, iris category,
habitual lens type will be included as fixed effects when appropriate.  
Hypothesis TestingThe null and alternative hypothese s for testing superiority of the Test lens relative to the 
Control lens with respect to end of day comfort are as follows: 
‹™
‡¨¥:  ‹¥‹± ‡µë 1
‹™‡Æ∫:‹¥‹±>1
Where OR represents the odds ratio of having ‚ÄúVery Satisfied‚Äù or ‚ÄúSatisfied‚Äù rating for the 
Test lens compared to the Control at the 2-week follow-up. Comparisons between Test and
Control will be carried out using the 95% conf idence interval (CI) constructed for the odds 
ratio (Test over Control). Superiority will be declared if the lower bound of the 2-sided 95% confidence interval is above 1.  
14.6. Secondary Analyses  
Secondary analyses will be conducted on the Intent-to-Treat (ITT) population with observed 
cases (use only available datapoints and no imputation for missing data). 
CR-6481, v 3.0  
 
Page 53 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
All secondary endpoints will be analyzed separately using the same model as described for the 
primary endpoint. Item responses will be converted  into binary variables as follows: Excellent 
or Very Good = 1 and others = 0 for digital device use (‚ÄúReduction in the feeling of tired eyes from using a computer or other digital device‚Äù) and comfortable vision while night driving 
(‚ÄúAbility to see comfortably while driving at night‚Äù), and Strongly Agree or Agree = 1 and 
others = 0 for comfort throughout the day (‚ÄúI coul d wear these contact [CONTACT_163081] I wanted to‚Äù). 
According to the testing strategy presented in s ection 14, if the primary hypothesis is met, the 
secondary endpoints will be tested as follows:
xfor the first two secondary endpoints (digital device use and comfort throughout the 
day), comparisons between Test and Control will be carried out using the 
corresponding adjusted two-sided CI (96.25% CI for alpha = 0.0375 or 97.5% CI for 
alpha = 0.025), depending on the relative ma gnitude of the obtained nominal p-values,
constructed for the odds ratio (Test ove r Control) separately for each endpoint; 
xfor the last secondary endpoint (comfortable  vision while night driving), a two-sided 
95% CI (alpha = 0.05), 97.5% CI (alpha = 0.025), or 98.75% CI (alpha = 0.0125) will 
be estimated for odds ratio and the confiden ce level will be determined based on the 
success of the previously tested secondary endpoints. 
Superiority will be declared if the lower bound of the corresponding CI is above 1. 
14.7. Other Exploratory Analysis  
All other exploratory endpoints will be descri ptively summarized. A future planned post-hoc 
meta-analysis may be conduc ted using these endpoints.
14.8. Interim Analysis  
Not applicable
14.9. Procedure for Handling Missing Data and Drop-Outs
Missing or spurious values will not be imputed . The count of missing values will be included 
in the summary tables and listings. 
Subject dropout is expected to be one of the main reasons of missing data in this clinical trial. 
Past clinical trials don‚Äôt provide the evidence that subject dropout is systematic or not-at-
random. To evaluate the impact of missing da ta on the primary and secondary analyses,
sensitivity analysis may be conducted on th e ITT population using multiple imputation 
methods if the proportion of subject dropout is greater than 15%. The SAS/STAT procedures 
PROC MI and PROC MIANALYZE will be utilized  with a parametric regression method used 
to make at least 20 imputations.
14.10. Procedure for Reporting Deviations from Statistical Plan
The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate from these analysis methods. If for any reason 
CR-6481, v 3.0  
 
Page 54 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
a change is made, the change will  be documented in the study report along with a justification 
for the change.
15. DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645]/ARCHIVING
15.1. Electronic Case Report Form/Data Collection
The data for this study will be captured on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data originator will enter study data into the eCRFs 
using the EDC system. Data collected on equipment that is not captured in EDC will be
formatted to the specification of the JJVC database manager and sent to JJVC for analysis. 
External data sources for this study include: Not Applicable .
The clinical data will be recorded on dedicated eCRFs specifically designed to match the study 
procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_3786]. The sponsor or sponsor‚Äôs representatives will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study. 
Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and 
complete data collection. Data will be transmitted from the clinical site to a secure central 
database as forms are completed or updated,  ensuring information accuracy, security, and 
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit trai l on electronic media in PDF format for all of 
the study data. The IPP must be retained in the st udy files as a certified copy of the source data 
for the study. 
The content and structure of the eCRFs are compliant with ISO14155:2020.
[ADDRESS_189361] should be available for the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
xresults of safety and efficacy parameters as required by [CONTACT_35526]-up of adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
CR-6481, v 3.0  
 
Page 55 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xdate of study completion
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.
Adverse event notes must be reviewed and initialed by [CONTACT_737].
15.3. Trial Registration on ClinicalTrials.gov 
This study will be registered on ClinicalTrials.gov by [CONTACT_1034].
16. DATA MANAGEMENT
16.1. Access to Source Data/Document
The Investigator/Institution will permit trial-re lated monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the 
clinical site be contact[CONTACT_129816]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_19592] [ADDRESS_189362] and therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clinical study, th e Investigator understands that he/she has an 
obligation to provide complete test results a nd all data developed during this study to the 
Sponsor. 
16.3. Data Quality Assurance
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical s ites and review of protocol procedures with 
the Principal Investigator. The Principal Invest igator, in turn, must ensure that all Sub-
Investigators and clinical site personnel are fa miliar with the protocol and all study-specific 
procedures and have appropriate  knowledge of the study article.
Training on case report form completion will be provided to clinical site personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, 
as appropriate.
CR-6481, v 3.0  
 
Page 56 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Quality Assurance representatives from JJVC may vi sit clinical sites to review data produced 
during the study and to access compliance with appl icable regulations pertaining to the conduct 
of clinical trials. The clinical sites will provide direct access to study-related source 
data/documents and reports for the purpose of monitoring and auditing by [CONTACT_71182].
16.4. Data Monitoring Committee (DMC)
Not applicable
17. CLINICAL MONITORING
The study monitors will maintain close contact  [CONTACT_35530] [INVESTIGATOR_35453]‚Äôs designated clin ical site personnel. The mon itor‚Äôs responsibilities will include:
xEnsuring that the investigation is being conducted according to the protocol, any 
subsequent versions, and regulat ory requirements are maintained. 
xEnsuring the rights and wellbeing  of subjects are protected. 
xEnsuring adequate resources, including f acilities, laboratories, equipment, and 
qualified clinical site personnel. 
xEnsuring that protocol deviations are docum ented with corrective action plans, as 
applicable. 
xEnsuring that the clinical site has sufficient test article and supplies. 
xClarifying questions regarding the study. 
xResolving study issues or problems that may arise. 
xReviewing of study records and source documentation verification in accordance with 
the monitoring plan. 
18. ETHICAL AND REGULATORY ASPECTS
18.1. Study-Specific Design Considerations
Potential subjects will be fully informed of th e risks and requirements of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
participation. Subjects will be told that their consent to participate in the study is voluntary and 
may be withdrawn at any time with no reason give n and without penalty or  loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the subject is fully 
able to understand the risks, benefits, and potential adverse events of the study and provide
their consent voluntarily . 
18.2. Investigator Responsibility
The Principal Investigator [INVESTIGATOR_71157], the investigational plan, section 4 of the ICH E6(R2)
guidelines on Good Clinical Practice (GCP),2and applicable regulatory requirements. GCP is 
an international ethical and sc ientific quality standard for designing, conducting, recording, 
CR-6481, v 3.0  
 
Page 57 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
and reporting studies that involve the participa tion of human subjects. Compliance with this 
standard provides public assurance that the right s, safety, and well-being of study subjects are 
protected, consistent with the principl es of the Declaration of Helsinki 64thWMA General 
Assembly 20133and that the clinical study data are cred ible. The Investigator must maintain 
clinical study files in accordance with section 8 of the ICH E6(R2) guidelines on Good Clinical 
Practice (GCP),2and applicable regulatory requirements.
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB)
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (where applicable):
xFinal protocol. 
xSponsor-approved informed consent form (a nd any other written materials to be 
provided to the subjects)
xInvestigator‚Äôs Brochure (or equivalent information). 
xSponsor-approved subject recruitment materials. 
xInformation on compensation for study-related injuries or payment to subjects for 
participation in the study. 
xInvestigator‚Äôs curriculum vitae, clinical licenses, or equivalent information (unless not required, as documented by [CONTACT_8134]/IRB). 
xInformation regarding funding, name [CONTACT_35596] e Sponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for subjects. 
xAny other documents that the IEC/IRB requests to fulfill its obligation. 
This study will be undertaken only after IEC/IRB ha s given full approval of the final protocol,
the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of this approval. This a pproval letter must be 
dated and must clearly identify  the documents being approved.
During the study, the Investigator (or Sponsor when applicable) will send the following documents to the IEC/IRB for their revi ew and approval, where appropriate:
xProtocol revisions 
xRevision(s) to informed consent form and an y other written materials to be provided to 
subjects
xIf applicable, new or revised subject recr uitment materials approved by [CONTACT_89634]-related injuries or payment to subjects for participation in the study
xInvestigator‚Äôs Brochure revisions  
xSummaries of the status of the study (at least annually or at intervals stipulated in 
guidelines of the IEC/IRB)
xReports of adverse events that are serious, unanticipated, and associated with the test 
articles, according to the IRB‚Äôs requirements
CR-6481, v 3.0  
 
Page 58 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xNew information that may adversely affect th e safety of the subjects or the conduct of 
the study
xMajor protocol deviations as required by [CONTACT_6179]/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Investigator is responsible for the study at the clinical site
xAny other requirements of the IEC/IRB
For protocol revisions that increase subject risk , the revisions and applicable informed consent 
form revisions must be submitted promptly to  the IEC/IRB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this notification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consent
Each subject or their representative, must give written consent according to local requirements after the nature of the study has been fully expl ained. The consent form must be signed before 
performance of any study-related activity. The consen t form that is used must be approved by 
[CONTACT_19597]/IRB. The informed consent is in accordance with 
principles that originated in the Declaration of Helsinki,
3current ICH GCP2and ISO 
[ZIP_CODE]:[ADDRESS_189363] 's dated signature. After having obtained the 
consent, a copy of the informed consent form must be given to the subject.
18.5. Privacy of Personal Data
The collection, processing and disclosure of pe rsonal data and medical information related to 
the Study Subject, and personal data  related to Principal Investig ator and any clinical site 
personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portability and Accountability Act (HIPAA) and otherapplicable personal data  protection and security laws and regulations.
12,[ADDRESS_189364] these data, to maintain the confidentiality of the person‚Äôs related health and medi cal information, to properly inform the concerned persons 
CR-6481, v 3.0  
 
Page 59 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
about the collection and processing of their pers onal data, to grant them reasonable access to 
their personal data and to prevent access by [CONTACT_35532].
All information obtained during the course of the investigation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by [CONTACT_4718], 
monitors, Sponsor‚Äôs personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subject concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulat ory organizations in the context of their 
investigation related ac tivities that, as part of the investigation will have access to the CRFs 
and subject records.
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to inves tigate the efficacy, safety, quality, and utility of 
the investigational product(s) used in this study.These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations.
The Sponsor ensures that the personal data will be:
xprocessed fairly and lawfully. 
xcollected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes. 
xadequate, relevant, and not excessi ve in relation to said purposes. 
xaccurate and, where necessary, kept current. 
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent s hould also address the transfer of the data to 
other entities and to other countries.
The subject has the right to request through the Investigator access to his personal data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps 
should be taken to respond to such a request, taki ng into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations.
Appropriate technical and orga nizational measures to protect the personal data against 
unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pe rsonnel whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential. 
19. STUDY RECORD RETENTION
In compliance with the ICH GCP guidelines,
2the Investigator/Institution will maintain all 
CRFs and all subject records that support the da ta collected from each subject, as well as all 
study documents as specified in ICH GCP2and all study documents as specified by [CONTACT_12926](s). The Inves tigator/Institution will take  measures to prevent 
accidental or premature destruction of these documents.
CR-6481, v 3.0  
 
Page 60 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Essential documents must be retained until at least two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical developm ent of the investigational product. These 
documents will be retained for a longer peri od if required by [CONTACT_35533]. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained.
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of the name [CONTACT_19619]. Under no circumstance shall th e Investigator relocate or dispose of any 
study documents before having obtaine d written approval from the Sponsor. 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any documentation relating to this study, the Inves tigator must permit access to such reports.  
If the Investigator has a question regarding retention of study records, he/she should contact [CONTACT_19599].
20. FINANCIAL CONSIDERATIONS
Remuneration for study services and expenses will be set forth in detail in the Clinical Research 
Agreement. The Research Agreement will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management representative prior to study initiation.
JJVC reserves the right to withhold remuneration fo r costs associated with protocol violations 
such as:
xContinuing an ineligible subject in the study. 
xScheduling a study visit outside the subject‚Äôs acceptable visit range. 
JJVC reserves the right to withhold final rem uneration until all study related activities have 
been completed, such as:
xQuery resolution. 
xCase Report Form signature. 
xCompletion of any follow-up action items. 
21. PUBLICATION
This is a multicenter study. The participating inst itution and Principal Investigations for this 
study agree that, should this study results be published, the first publication of the results of 
this study shall be made in conjunction with th e presentation of a joint, multicenter publication 
of the study results with the investigators a nd the institutions from all appropriate sites 
contributing data, analyses and comments.
CR-6481, v 3.0  
 
Page 61 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
22. REFERENCES
1. ISO [ZIP_CODE]:2020: Clinical Investigation of  Medical Devices for Human Subjects ‚Äî
Good Clinical Practice. Available at https://www.iso.org/standard/[ZIP_CODE].html
2. International Conference on Harmonizati on Good Clinical Practice E6 (ICH-GCP). 
Available at http://www.ich.org/products/guidelin es/efficacy/article/efficacy-
guidelines.html  
3. Declaration of Helsinki - Ethical prin ciples for Medical Research Involving Human 
Subjects. Available at https://www.wma.net/policies-post/wma-declaration-of-
helsinki-ethical-principles-for-me dical-research-invol ving-human-subjects/
4. [LOCATION_002] (US) Code of Federa l Regulations (CFR). . Available at 
https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR   
5.  SAS Institute Inc. 2016 SAS/STAT¬Æ 14.3 User‚Äôs Guide. Cary, NC: SAS Institute Inc.   
6. Buch J. Clinical Study Report Evaluation of Prototype 
Lenses with Experimental UV/HEV Blocker  
7. Buch J. Clinical Study Report Vision Evaluation of 
Contact [CONTACT_163082]/HEV Filter  December 08, 2021.
8. Buch J. Clinical Study Reports Evaluation of Prototype 
Lenses with Experimental UV/HEV  November 11, 2021.
9. Buch J. Clinical Study Report  Validation of senofilcon 
A with new UV/HEV Filter  January 12, 2022.
10. Dmitrienko A, Tamhane AC, Wiens BL. Ge neral Multistage Gate keepi[INVESTIGATOR_163062]. 
Biometrical Journal. 2008;50(5):667-677. 
11. Dmitrienko A, Kordzakhia G, Tamhane AC. Multistage and Mixture Parallel 
Gatekeepi[INVESTIGATOR_163063]. Journal of Biopharmaceutical Statistics. 
2011;21(4):726-747. 
12. Health Information Portability and Accountability Act (HIPAA). Available at 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html   
13. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 
2017 on medical devices. Available at http://data.europa.eu/eli/reg/2017/745/2017-
05-05
CR-6481, v 3.0  
 
Page 62 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)
CR-6481, v 3.0  
 
Page 63 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6481, v 3.0  
 
Page 64 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6481, v 3.0  
 
Page 65 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
CR-6481, v 3.0  
 
Page 66 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
CR-6481, v 3.0  
 
Page 67 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
CR-6481, v 3.0  
 
Page 68 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
CR-6481, v 3.0  
 
Page 69 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
CR-6481, v 3.0  
 
Page 70 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
CR-6481, v 3.0  
 
Page 71 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
CR-6481, v 3.0  
 
Page 72 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
CR-6481, v 3.0  
 
Page 73 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 11
CR-6481, v 3.0  
 
Page 74 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 12
CR-6481, v 3.0  
 
Page 75 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 13
CR-6481, v 3.0  
 
Page 76 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 14
CR-6481, v 3.0  
 
Page 77 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 15
CR-6481, v 3.0  
 
Page 78 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 16
CR-6481, v 3.0  
 
Page 79 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 17
CR-6481, v 3.0  
 
Page 80 of 135JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 18
CR-6481, v 3.0  
 
Page 81 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE   
The Patient Instruction Guide (PIG ) will be provided separately.
CR-6481, v 3.0  
 
Page 82 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)
DAILIES TOTAL1¬ì  
CR-6481, v 3.0  
 
Page 83 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 LENS FITTING CHARACTERISTICS
CR-6481, v 3.0  
 
Page 87 of 135JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 1of 5CR-6481, v 3.0  
 
Page 88 of 135JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 2of 5CR-6481, v 3.0  
 
Page 89 of 135JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 3of 5CR-6481, v 3.0  
 
Page 90 of 135JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 4of 5CR-6481, v 3.0  
 
Page 91 of 135JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 5of 5CR-6481, v 3.0  
 
Page 92 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS  
CR-6481, v 3.0  
 
Page 93 of 135JJVC CONFIDENTIAL
Title:                          Subject Reported Ocular Symptoms/Problems
Document Type:  
Document Number: Revision Number:  4 
CR-6481, v 3.0  
 
Page 94 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
FRONT AND BACK SURFACE LENS DEPOSIT GRADING PROCEDURE  
CR-6481, v 3.0  
 
Page 95 of 135JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 4CR-6481, v 3.0  
 
Page 96 of 135JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 4CR-6481, v 3.0  
 
Page 97 of 135JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 4CR-6481, v 3.0  
 
Page 98 of 135JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 4CR-6481, v 3.0  
 
Page 99 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIVE ERROR 
CR-6481, v 3.0  
 
Page 100 of 135JJVC CONFIDENTIAL
Title:                           De termination of Distance Spherocylindrical Refractive Error
Document Type:  
Document Number: Revision Number:  5 
CR-6481, v 3.0  
 
Page 101 of 135JJVC CONFIDENTIAL
Title:                           De termination of Distance Spherocylindrical Refractive Error
Document Type:  
Document Number: Revision Number:  5 
CR-6481, v 3.0  
 
Page 102 of 135JJVC CONFIDENTIAL
Title:                           De termination of Distance Spherocylindrical Refractive Error
Document Type:  
Document Number: Revision Number:  5 
CR-6481, v 3.0  
 
Page 103 of 135JJVC CONFIDENTIAL
Title:                           De termination of Distance Spherocylindrical Refractive Error
Document Type:  
Document Number: Revision Number:  5 
CR-6481, v 3.0  
 
Page 104 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 BIOMICROSCOPY SCALE  
CR-6481, v 3.0  
 
Page 106 of 135JJVC CONFIDENTIAL
Title:      Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  10 
Page 1 of 5
CR-6481, v 3.0  
 
Page 107 of 135JJVC CONFIDENTIAL
Title:      Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  10 
Page 2 of 5
CR-6481, v 3.0  
 
Page 108 of 135JJVC CONFIDENTIAL
Title:      Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  10 
Page 3 of 5
CR-6481, v 3.0  
 
Page 109 of 135JJVC CONFIDENTIAL
Title:      Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  10 
Page 4 of 5
CR-6481, v 3.0  
 
Page 110 of 135JJVC CONFIDENTIAL
Title:      Biomicroscopy Scale
Document Type:
Document Number:       Revision Number:  10 
Page 5 of 5
CR-6481, v 3.0  
 
Page 111 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION  
CR-6481, v 3.0  
 
Page 112 of 135JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 
CR-6481, v 3.0  
 
Page 114 of 135JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 
CR-6481, v 3.0  
 
Page 115 of 135JJVC CONFIDENTIAL
Title:                          Distance and Near Snelle n Visual Acuity Evaluation
Document Type:  
Document Number: Revision Number:  5 
CR-6481, v 3.0  
 
Page 116 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 PATIENT REPORTED OUTCOMES 
CR-6481, v 3.0  
 
Page 117 of 135JJVC CONFIDENTIAL
Title: Patient Reported Outcomes
Document Type:
Document Number: Revision Number: 3
Page 1of 1
CR-6481, v 3.0  
 
Page 118 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
WHITE LIGHT LENS SURFACE WETTABILITY  
CR-6481, v 3.0  
 
Page 119 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX F: STARTING LENS POWER GUIDANCE
CR-6481, v 3.0  
 
Page 122 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX G: GUIDELINES FOR COVID-19 RISK MITIGATION
CR-6481, v 3.0  
 
Page 123 of 135JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PROTOCOL COMPLIANCE INVEST IGATOR(S) SIGNATURE [CONTACT_19620]: CR-6481 Clinical pe rformance of senofilcon A investigational lens 
Version and Date: 3.[ADDRESS_189365] this study according to ISO [ZIP_CODE]:2020,
1GCP and ICH guidelines,2the 
Declaration of Helsinki,3[LOCATION_002] (US) Code of  Federal Regulations (CFR),4and the 
pertinent individual country laws /regulations and to comply with its obligations, subject to 
ethical and safety considerations. The Principal Investigator [INVESTIGATOR_163064], including S ub-Investigators adhere to all ICH2regulations and GCP 
guidelines regarding clinical tria ls during and after study completion.
I will assure that no deviation from or changes to the protocol will take place without prior 
agreement from the Sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including S ub-Investigators adhere 
to all ICH2regulations and GCP guidelines regarding clinical trials during and after study 
completion. All clinical site personnel i nvolved in the conduct of this  study have completed Human 
Subjects Protection Training. I agree to ensure that all clinical site pe rsonnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitments.I shall not disclose the information contained in this protocol or any results obtained from this 
study without written authorization.I have read the suggested guidance provided by [CONTACT_19610]-19 risk 
mitigation, (COVID-19 Work Instruction in the Appendix G of this protocol). I agree to 
conduct this study in compliance with local, st ate, governmental guidance for COVID-19 risks.
Principal 
Investigator:
[INVESTIGATOR_19540] (Printed)
Institution/Site:
Institution/Site Name
[CONTACT_16277]/Site Address
CR-6481, v 3.0  
 
Page 135 of 135JJVC CONFIDENTIAL